21 results about "Aortic wall" patented technology

The invention relates to the technical field of neutrophile granulocyte separation, in particular to a mouse neutrophile granulocyte separation method which comprises the following steps: (1) anesthetizing and disinfecting a mouse; (2) tissue sampling; (3) tissue digestion; (4) preparing a cell suspension; (5) purifying cells; (6) cell culture; according to the method disclosed by the invention, isoflurane is adopted in the anesthesia disinfection step, so that central nervous activity of mice can be rapidly inhibited, tissue damage caused by stress reaction is avoided, and chemical stimulation can be reduced while body surface microorganisms are cleared through combination of ethanol disinfection and sterile normal saline flushing, and aortic tissues with intact activity are provided for subsequent material taking. In the compound enzyme digestive juice, collagenase I can specifically degrade aortic wall collagenous fibers, trypsin dissociates adhesion connection between cells, neutral protease assists in decomposing elastic fibers, and DNA enzyme I is supplemented to inhibit cell aggregation, so that the contradiction between incomplete digestion and large cell damage of the traditional enzyme juice is effectively solved.

The utility model discloses an aortic arch support which comprises a body, the body is arranged to be in a pre-bending shape, a concave portion is arranged on the body, and a first branch pipe, a second branch pipe and a third branch pipe which are matched with an aortic arch are arranged on the concave portion. The first branch pipe, the second branch pipe and the third branch pipe all protrude out of the surface of the body; according to the aortic arch support, a gap can be formed between the concave part and the aortic wall, the aortic arch support is suitable for most branch variation situations, and the phenomenon that the inner diameter of the aortic trunk is reduced cannot occur; besides, the contact area of the branch blood vessel and the main blood vessel can be increased, and the contact area is changed into a surface from a point, so that the phenomenon of internal leakage is well avoided; and the aortic arch stent is integrally designed, so that the integrity of the whole stent does not need to be damaged in an operation, and the risk is low.

The invention discloses a proximal anastomosis auxiliary device in coronary artery bypass grafting, and relates to the technical field of medical instruments. Comprising a puncture needle, a puncture cannula and an annular compressor. The puncture needle is sleeved with the puncture cannula, and a bulged ball is arranged at the head end of the puncture cannula; the annular compressor is arranged outside the puncture cannula in a sleeving mode and can slide in the axial direction, a compression ring with a notch is arranged at the head end of the annular compressor, and the inner diameter of the compression ring is smaller than the outer diameter of the bulging ball. During puncture, the annular compressor is pressed down after puncture enters the aorta, and the compression ring and the bulging ball cooperate to clamp and close a puncture point to achieve blood-free operation; after the aorta wall in the compression ring is cut off, the bridge vessel is matched with the aorta, and the suture passes through the compression ring together; after suturing is completed, the annular compressor is rotated, the suture retreats from the notch, the suture is tightened and knotted after the whole device is withdrawn, and anastomosis is completed. The aorta forceps clip operation is avoided, the plaque falling risk is eliminated, anastomosis can be completed only through a single hole, operation is easy and convenient, hemostasis is reliable, and cost is low.

The invention provides a biomarker composition and an application thereof. The biomarker composition comprises the following proteins: MMP12, UMOD, HbA1c, FGF9, NINJ1 and PRSS8. According to the biomarker composition provided by the invention, through combination of matrix metalloproteinase 12, uromodulin, glycosylated hemoglobin, FGF9, NINJ1 and serine protease 8, the problem of lack of a specific marker for aortic wall structure damage in the prior art is solved.

The present application relates to the application of delta-Viniferin in the preparation of drugs for preventing or treating metabolic cardiovascular diseases. Delta-Viniferin can inhibit the expression level of aging and inflammation related genes / proteins of vascular endothelial cells, reduce endothelial dysfunction, and clarify its anti-hypertensive effect. Delta-Viniferin can inhibit the expression level of vascular smooth muscle cell phenotype conversion related genes / proteins, improve the contraction function of vascular smooth muscle, and significantly alleviate the degradation of elastic fibers of the vascular wall and the rupture of the intima of the aortic wall in vivo, and clarify its effect on preventing and treating aortic dissection. Delta-Viniferin can inhibit the expression level of myocardial fibroblast fibrosis related genes / proteins, and clarify its anti-myocardial fibrosis effect. Delta-Viniferin can promote white adipose tissue browning by targeting the SIRT1-FOXO1 axis, increase energy consumption, and clarify its effect on resisting obesity. In summary, the compound delta-Viniferin has the effect of protecting various metabolic cardiovascular diseases, and can be used to prepare drugs for preventing and treating metabolic cardiovascular diseases.

The present invention relates to the technical field of medical devices for cardiovascular diseases. Disclosed is an aortic covered stent. The aortic covered stent comprises a supporting stent, a sealing layer, and an elastic connecting layer. The sealing layer is spaced apart from and sleeved on the outer periphery of the supporting stent. The sealing layer comprises a first covering film. The elastic connecting layer is connected between the supporting stent and the sealing layer, such that blood flow can circulate between the supporting stent and the sealing layer. With the pulsation of the aorta, the sealing layer and the elastic connecting layer undergo elastic deformation, so that the first covering film is always closely attached to the aortic blood vessel wall adjacent to the sealing layer. The aortic covered stent can be well adapted to the special morphology of ascending aortic dissection and the mechanical characteristics of blood flow, offering high stability and exhibiting good sealing performance on the ascending aortic wall.

The application provides a valve stent and artificial valve, which comprises a stent body, a plurality of first support arms arranged along the circumference of the stent body, one end of the first support arm being connected with the outflow end of the stent body, the other end being arranged outside the stent body and extending towards the inflow end of the stent body, and a second support arm, one end of the second support arm being connected with the outflow end of the stent body, the other end being arranged outside the stent body; the stent body can be placed at the aortic valve, the stent body and the first support arm accommodate the native valve leaflet, the other end of the first support arm extends into the corresponding aortic sinus to provide anchoring, at least one first support arm can be arranged in each aortic sinus, and the second support arm can support the aortic wall. The application can replace the aortic valve regurgitation, realize stable and reliable anchoring through the unique anchoring structure, and is not easy to block the coronary artery opening.

The invention discloses a personalized valved aorta model manufacturing method based on iconography data, and belongs to the technical field of experimental apparatus design methods. The core innovation of the method is that an interlayer wrapping integrated forming process is adopted to replace a traditional bonding method. The method comprises the following steps: firstly, manufacturing a flexible valve assembly comprising valve leaflets, part of sinus canal walls and part of left ventricular outflow tracts by utilizing a special valve dipping mold; then, an aorta spin-coating mold with a reserved valve mounting position is used, preliminary spin-coating is conducted firstly, part of the aorta wall is formed, then the prefabricated valve assembly is mounted at the reserved position of the aorta mold, and then spin-coating continues to be conducted. In the process, a base (part of the sinus canal wall) of the valve assembly is seamlessly wrapped and fused into a silica gel layer of the aorta wall. And finally, dissolving the internal mold to obtain a seamless model in which the valve and the aorta are completely fused into a whole.

This invention relates to the field of finite element stress calculation technology, specifically to an aortic stress calculation system based on finite element analysis. In this invention, multiple sets of aortic displacement vectors and element stress vectors are spliced ​​into a response matrix according to the sequence of nodal degrees of freedom and element numbering. The Gram-Schmidt orthogonalization method is introduced to process the retained vectors, compressing the directional coincident components and linearly correlated components, resulting in stronger stability of the reduced-order basis space and smoother conversion of high-dimensional discrete equations to low-dimensional expressions. The Newton-Raphson algorithm is introduced in the path state update stage, where load step difference, nodal displacement increment, and integral point stress tensor are continuously recorded. The path turning state and load propagation form are adjusted synchronously. Facing high internal pressure, large deformation, and nonlinear response scenarios, peak tracking continuity is stronger, the frequency of solving repeated integral models is reduced, the high-risk area of ​​the aortic wall is more concentrated, and the numerical support for scheme comparison, parameter scanning, and risk pre-assessment is more sufficient.

The present application relates to cardiovascular disease medical equipment technical field, disclose a kind of aortic covered stent, the aortic covered stent includes support stent, closure layer and elastic connecting layer, closure layer is spaced apart and is set to the outer periphery of support stent, closure layer includes first covering, elastic connecting layer is connected between support stent and closure layer, blood flow can flow between support stent and closure layer;With aortic pulsation, closure layer and elastic connecting layer produce elastic deformation, so that first covering is always close to aortic and the blood vessel wall adjacent to closure layer.The aortic covered stent can be better applied to the special form of ascending aortic dissection and the mechanical characteristics of blood flow, higher stability, better closure for ascending aortic wall.

The application discloses a blood pressure calculation method and equipment based on cross-scale fluid-solid coupling and considering nonlinear biomechanical characteristics of an aorta, and the method comprises the following steps: establishing a three-dimensional ideal aorta geometric model; establishing a zero-dimensional heart lumped parameter model to simulate the process that the heart pumps blood to the aorta inlet through periodic contraction and diastole; establishing a zero-dimensional three-element Windkessel model of small arteries to simulate blood flow microcirculation of peripheral small arteries; establishing a blood vessel wall biomechanical model containing residual stress of the aorta wall and active contraction of smooth muscle cells to obtain a pressure-radius relationship of the aorta wall as a fluid wall boundary condition to simulate the change process of the aorta radius in blood circulation; and coupling the three-dimensional ideal geometric model of the aorta, the zero-dimensional heart lumped parameter model and the zero-dimensional three-element Windkessel model to construct a cross-scale fluid-solid coupling system of hemodynamics, and the blood pressure in the aorta is calculated through iterative solution.

The invention discloses an application of valerian triester in preparation of products for preventing and treating aortic dissection, which can reduce the occurrence rate of aortic events, relieve the reduction of survival rate caused by aortic dissection, inhibit aortic dilatation caused by aortic dissection, reduce the number of elastic fiber fractures caused by aortic dissection and improve the survival rate of aortic dissection. The hematoma and the false cavity between aortic walls caused by the aortic dissection are improved, and the structural damage of the aortic walls caused by the aortic dissection is improved. According to the technical scheme provided by the invention, a brand new compound option is provided for the drug treatment of the aortic dissection.

The utility model discloses an aortic cannula, and relates to the technical field of aortic cannulas. Comprising a cannula body, a first positioning airbag, a second positioning airbag and a connecting hose. The first positioning air bag and the second positioning air bag are arranged on the outer side of the cannula body and can be tightly pressed on the inner side and the outer side of an aorta adventitia respectively during use, and the problems that high-pressure blood flow enters an aorta cavity, and aorta dissection or false aneurysm is formed are solved; meanwhile, when the intubation tube body needs to be separated from extracorporeal circulation for tube drawing operation, air in the second positioning air bag is completely discharged, then the intubation tube body is pulled out, the first positioning air bag can play a role in blocking sprayed blood flow, and the operator can be effectively protected; the problems that in a traditional aortic cannula, the aortic wall structure is prone to being damaged in the cannula inserting process, and false aneurysm or aortic dissection is formed are solved; the blood pressure in the aorta blood vessel is high, the purse string is easy to avulsion, the aorta wall is damaged, and the intubation tube is easy to fall off.

The invention belongs to the technical field of biological medicine, and particularly discloses application of a bioactive composition in prevention, treatment and improvement of aortic dissection. The invention provides application of a bioactive composition in preparation of a medicine for preventing, treating and improving aortic dissection. The bioactive composition comprises docosahexaenoic acid and resveratrol. The invention discloses application of a bioactive composition in prevention, treatment and improvement of aortic dissection, and the aortic dissection is treated by repairing damaged aortic wall, retarding aortic dilatation, protecting elastic structure of aortic smooth muscle layer and recovering elastic phenotype of smooth muscle cells.

The three-legged aortic valve forceps comprise three supporting arms and an outer ring, the supporting arms are elastic and can be folded inwards, measuring rings are connected to the outer sides of the supporting arms in a sleeving mode, grabbing parts are arranged at the lower ends of the supporting arms, the upper ends of the supporting arms are fixedly connected, the lower sides of the supporting arms are separated and unfolded outwards, and the outer ring is arranged on the outer ring. The valve leaflet clamping device has the advantages that the valve leaflet can be rapidly and safely clamped and fixed, and the inner diameter of a prosthesis for replacing the aorta wall can be measured in an auxiliary mode.

Cannulas for apical cannulation and methods of making and using the same are provided. The cannula includes a first elongated body defining a primary lumen, a second elongated body defining a first secondary lumen, a third elongated body defining a second secondary lumen, and a fourth elongated body defining a third secondary lumen. The primary lumen is configured to allow blood to flow therethrough. The first secondary lumen is configured to inflate an inflatable body, which is configured to engage an aortal wall proximate the aortic valve of the patient's heart to define a treatment space. The second secondary lumen is configured to selectively remove blood from the treatment space or introduce a cardioplegic solution into the treatment space. The third secondary lumen is configured to administer active decompression of the left ventricle of the patient's heart via suction.

An auxiliary device for proximal aortic anastomosis in coronary artery bypass grafting (CABG) includes a puncture needle, a puncture cannula, a cutting cannula, and a ring compressor. The puncture cannula is fitted over the puncture needle, with a bulging ball at its tip and an annular groove at its tail end. The ring compressor is fitted over the puncture cannula and can slide axially; its tip has a notched compression ring with an inner diameter smaller than the outer diameter of the bulging ball. During puncture, after the aorta is penetrated, the ring compressor is pressed down, and the compression ring and bulging ball work together to clamp the puncture site, achieving a bloodless procedure. The cutting cannula is then pressed down, and the aortic wall within the compression ring is removed. The graft vessel is then anastomosed to the aorta, with the suture passing through the compression ring. After suturing, the ring compressor is rotated, and the suture exits through the notch. The entire device is then withdrawn, and the suture is tightened and knotted to complete the anastomosis. This invention avoids aortic clamping, eliminates the risk of plaque dislodgement, requires only a single port for anastomosis, and is simple to operate with reliable hemostasis.

This invention discloses the application of targeting the PDGFD gene in the treatment of hypertension. This invention demonstrates in a mouse model of angiotensin II-induced hypertension that systemic knockout... Pdgfd It can significantly lower blood pressure, reduce aortic wall thickening, and decrease the vessel wall-to-lumen ratio. In vitro vascular ring experiments confirmed that knocking out PDGFD can enhance vascular elasticity. In summary, PDGFD is a key new target for regulating blood pressure, and its inhibitors or gene interventions can be used to prepare antihypertensive drugs, providing new strategies for precision treatment of hypertension.

The invention discloses a suture-free flexible patch for external reinforcement of aortic aneurysm, and belongs to the field of vascular surgery medical instruments. A flexible main body with in-situ adhesion is adopted, and the flexible main body is formed by compounding a fiber stent sheet and a high polymer material, is directly attached to the outer wall of the aortic aneurysm from the outside, and is assisted by photo-crosslinking to form a composite reinforcing layer on the surface of the aortic aneurysm in situ, so that the blood flow pressure is shared, and the critical rupture pressure of the aortic aneurysm is improved. The material is composed of biocompatible macromolecules, the elasticity modulus and the overall mechanical property of the material are close to those of a healthy aorta wall, the problems of tissue tearing risks caused by suture and poor mechanical property are solved, the material is suitable for minimally invasive surgery, aorta blood flow does not need to be cut open and blocked, and a traditional excision replacement surgery is effectively replaced.

The invention discloses an application of a targeted PDGFD gene in hypertension treatment. In an angiotensin II induced hypertension mouse model, it is proved that whole-body knockout of Pdgfd can significantly reduce blood pressure, relieve aorta vascular wall thickening and reduce the vascular wall-cavity ratio. An in-vitro vascular ring experiment proves that the blood vessel elasticity can be enhanced by knocking out the PDGFD. In conclusion, the PDGFD is a key new target for regulating and controlling blood pressure, and an inhibitor or a gene intervention means of the PDGFD can be used for preparing antihypertensive drugs, so that a new strategy is provided for precise treatment of hypertension.

The invention discloses a biomarker for predicting the onset risk of aortic dissection, a kit and application. The invention provides application of a reagent for detecting the SERPINE1 level of peripheral blood in preparation of products for aortic dissection attack risk prediction, early screening, diagnosis or curative effect monitoring. The marker and the related detection kit can be used for predicting the occurrence risk of the aortic dissection, and are not limited to diagnosis of the occurred dissection; the method is suitable for screening and dynamic follow-up visit of high-risk groups; the operation is simple and convenient, and a detection sample can be obtained through peripheral blood; the aortic wall pathological remodeling and fibrinolytic / matrix stability change can be reflected. Clinical sample verification shows that the method for predicting the onset risk of the aortic dissection through the SERPINE1 level of the peripheral blood has relatively high sensitivity and specificity, and relatively high clinical application value and application prospect are shown.